272 related articles for article (PubMed ID: 32827019)
1. Blood-based Biomarkers for Early Diagnosis of Lung Cancer: A Review Article.
Maharjan N; Thapa N; Tu J
JNMA J Nepal Med Assoc; 2020 Jul; 58(227):519-524. PubMed ID: 32827019
[TBL] [Abstract][Full Text] [Related]
2. Circulating MicroRNAs as Potential Biomarkers for Lung Cancer.
Müller S; Janke F; Dietz S; Sültmann H
Recent Results Cancer Res; 2020; 215():299-318. PubMed ID: 31605236
[TBL] [Abstract][Full Text] [Related]
3. Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression.
Grimolizzi F; Monaco F; Leoni F; Bracci M; Staffolani S; Bersaglieri C; Gaetani S; Valentino M; Amati M; Rubini C; Saccucci F; Neuzil J; Tomasetti M; Santarelli L
Sci Rep; 2017 Nov; 7(1):15277. PubMed ID: 29127370
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy for lung cancer screening: Usefulness of circulating tumor cells and other circulating blood biomarkers.
Hofman P
Cancer Cytopathol; 2021 May; 129(5):341-346. PubMed ID: 33007153
[TBL] [Abstract][Full Text] [Related]
5. Liquid biopsy for cancer diagnosis and screening - The promise and challenges.
Thorat MA
Ann Clin Biochem; 2019 Jul; 56(4):420-423. PubMed ID: 30971101
[No Abstract] [Full Text] [Related]
6. A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer.
Halvorsen AR; Bjaanæs M; LeBlanc M; Holm AM; Bolstad N; Rubio L; Peñalver JC; Cervera J; Mojarrieta JC; López-Guerrero JA; Brustugun OT; Helland Å
Oncotarget; 2016 Jun; 7(24):37250-37259. PubMed ID: 27191990
[TBL] [Abstract][Full Text] [Related]
7. Application of circulating genetically abnormal cells in the diagnosis of early-stage lung cancer.
Qiu X; Zhang H; Zhao Y; Zhao J; Wan Y; Li D; Yao Z; Lin D
J Cancer Res Clin Oncol; 2022 Mar; 148(3):685-695. PubMed ID: 33893839
[TBL] [Abstract][Full Text] [Related]
8. Role of circulating tumor DNA in the management of early-stage lung cancer.
Zhao H; Chen KZ; Hui BG; Zhang K; Yang F; Wang J
Thorac Cancer; 2018 May; 9(5):509-515. PubMed ID: 29528556
[TBL] [Abstract][Full Text] [Related]
9. [Research progress of circulating tumor DNA methylation in non-small cell lung cancer].
Yang Lan L; Chen Bojiang BJ; Li Lei L
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Dec; 41(12):967-970. PubMed ID: 30522195
[No Abstract] [Full Text] [Related]
10. Potential of circulating biomarkers in liquid biopsy diagnostics.
Yeo JC; Lim CT
Biotechniques; 2018 Oct; 65(4):187-189. PubMed ID: 30284936
[No Abstract] [Full Text] [Related]
11. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
Junqueira-Neto S; Batista IA; Costa JL; Melo SA
Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
[TBL] [Abstract][Full Text] [Related]
12. Circulating microRNAs as potential diagnostic biomarkers and therapeutic targets in prostate cancer: Current status and future perspectives.
Movahedpour A; Ahmadi N; Ghasemi Y; Savardashtaki A; Shabaninejad Z
J Cell Biochem; 2019 Oct; 120(10):16316-16329. PubMed ID: 31257636
[TBL] [Abstract][Full Text] [Related]
13. Advances of exosome isolation techniques in lung cancer.
Mahgoub EO; Razmara E; Bitaraf A; Norouzi FS; Montazeri M; Behzadi-Andouhjerdi R; Falahati M; Cheng K; Haik Y; Hasan A; Babashah S
Mol Biol Rep; 2020 Sep; 47(9):7229-7251. PubMed ID: 32789576
[TBL] [Abstract][Full Text] [Related]
14. The impact of extracellular vesicle-encapsulated circulating microRNAs in lung cancer research.
Fujita Y; Kuwano K; Ochiya T; Takeshita F
Biomed Res Int; 2014; 2014():486413. PubMed ID: 25295261
[TBL] [Abstract][Full Text] [Related]
15. [Progress of Liquid Biopsy in Early Diagnosis of Lung Cancer].
Song Z; Liu Y
Zhongguo Fei Ai Za Zhi; 2018 Aug; 21(8):620-627. PubMed ID: 30172270
[TBL] [Abstract][Full Text] [Related]
16. Diagnosing Lung Cancers through Examination of Micro-RNA Biomarkers in Blood, Plasma, Serum and Sputum: A Review and Summary of Current Literature.
Gyoba J; Shan S; Roa W; Bédard EL
Int J Mol Sci; 2016 Apr; 17(4):494. PubMed ID: 27043555
[TBL] [Abstract][Full Text] [Related]
17. Tumor-educated platelets.
In 't Veld SGJG; Wurdinger T
Blood; 2019 May; 133(22):2359-2364. PubMed ID: 30833413
[TBL] [Abstract][Full Text] [Related]
18. Screening for lung cancer: Who should be screened?
Jett J
Arch Pathol Lab Med; 2012 Dec; 136(12):1511-4. PubMed ID: 23194043
[TBL] [Abstract][Full Text] [Related]
19. Blood-based circulating tumor DNA mutations as a diagnostic and prognostic biomarker for lung cancer.
Leung M; Freidin MB; Freydina DV; Von Crease C; De Sousa P; Barbosa MT; Nicholson AG; Lim E
Cancer; 2020 Apr; 126(8):1804-1809. PubMed ID: 31999831
[TBL] [Abstract][Full Text] [Related]
20. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R
Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
